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Abstract
Background Human immunodeficiency virus (HIV) co-infection and chronic kidney disease add challenges to hepatitis C 
virus treatment. Objective To conduct a comparative study of treatment choices, drug–drug interactions and clinical outcomes 
in hepatitis C mono-infected patients, or those with HIV or chronic kidney disease comorbidities. Setting Hepatitis C treat-
ment centers of West Midlands England, United Kingdom. Method An observational study was conducted analyzing datasets 
of all hepatitis C patients that were referred to a large tertiary liver unit in the West Midlands, UK between July 2015 and 
January 2018. Patients aged ≥ 18 years with diagnosis of hepatitis C alone or co-infected with HIV or comorbid with chronic 
kidney disease were eligible. Main outcome measures The treatment choices, relevant potential drug–drug interactions and 
sustained virologic response 12 weeks post end of treatment were assessed. Results Out of 313 patients, 154 (49.2%) were 
hepatitis C mono-infected, 124 (39.6%) hepatitis C/HIV co-infected and 35 (11.2%) were hepatitis C/chronic kidney disease 
comorbid. There were 151 (98.1%) of hepatitis C mono-infected, 110 (88.7%) of hepatitis C/HIV and 20 (57.1%) of hepatitis 
C/chronic kidney disease patients treated with 1st line regimens. Significantly more patients who had co-morbidity with either 
HIV or chronic kidney disease were prescribed 2nd line regimens (8.1% and 37.1% respectively), compared to patients with 
hepatitis C mono-infection (1.9%) (P value < 0.05). Comorbid patients (12.1% of HIV and 25.8% of chronic kidney disease) 
were more likely to required drug–drug interactions advice (grade 5) than hepatitis C mono-infected (1.8%). Higher cure 
rates were observed in hepatitis C mono-infected (95.33%), hepatitis C/HIV (96.1%) compared to hepatitis C/chronic kidney 
disease patients (90.3%). Conclusion This study shows that treatment pathways permitting access to individual treatment 
adjustments in accordance with comorbidities and with consideration of drug–drug interaction in a multi-disciplinary team, 
provides successful outcomes in hepatitis C patients co-morbid with HIV or chronic kidney disease.
Keywords Chronic kidney disease · Clinical outcomes · Drug–drug interactions · Hepatitis C · HIV · Human immuno-
deficiency virus
Impacts on practice
• With treatment adjustments in accordance with comor-
bidities and with consideration of drug–drug interaction, 
it is possible to achieve high cure rates for hepatitis C 
patients who have HIV or chronic kidney disease.
• Input from multi-disciplinary team in decision mak-
ing for co-morbid hepatitis C infection is imperative in 
achieving desirable treatment outcomes.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1109 6-020-00994 -6) contains 
supplementary material, which is available to authorized users.
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Introduction
Comorbidities substantially impact on the progression 
and treatment of hepatitis C [1]. Globally, an estimated 71 
million people have chronic hepatitis C (CHC) [2]. In the 
United Kingdom (UK), about 160,000 people have CHC 
with injecting drug use (IDU) as the primary (~ 90%) 
mode of transmission [3]. The UK’s Government hepatitis 
C action plan for England, identifies the need to scale-up 
treatment with new antiviral drugs if the burden of CHC 
is to be managed. Treating hepatitis C patients along with 
the comorbidities presents a considerable challenge for the 
health care providers [4, 5].
Certain comorbidities in CHC-infected patients may 
affect treatment outcomes, impair health related quality of 
life (HRQOL) [6, 7], and increase mortality associated with 
liver complications [8, 9]. There are two co-morbidities par-
ticularly important in clinical practice when treating hepa-
titis C, namely, chronic kidney disease (CKD) and human 
immunodeficiency virus (HIV) infection. CKD patients are 
vulnerable to contracting hepatitis C during dialysis [10], 
if the procedure is carried out using poor sterilization prac-
tices. In the context of the UK, the number of patients with 
co-morbidity of HCV and CKD is significant and includes 
mainly patients who undergo frequent travel to South Asia 
or Africa and who receive dialysis treatment whilst on holi-
days [11–14].
Likewise, the co-morbidity of HIV is prevalent, particu-
larly in Injecting drug users (IDUs) [15]. Liver associated 
disease such as hepatitis C is a major reason of morbidity 
and mortality in HIV‐coinfection [16]. Also, HCV infec-
tion is being reported with increase in number among men 
who have sex with men (MSM) across Europe and the USA 
[17]. A Swiss cohort study has concluded that HCV infec-
tion accelerates the progression of HIV disease [18]. In 
HCV mono-infected patient, the progression of disease to 
cirrhosis takes almost 30 years in comparison to 15 years in 
co-infected patients [19].
The introduction of direct acting antivirals (DAAs) in 
2011, and the further development of pan-genotypic DAAs, 
has provided highly effective and tolerable HCV drug regi-
mens with cure rates greater than 95% [20]. However, in 
clinical practice, special considerations are required when 
prescribing DAAs for HCV/HIV co-infected patients due 
to concomitant medications and a potential increased risk 
of drug–drug interactions [21, 22]. Similarly, in HCV/CKD 
comorbidity, owing to accelerated development of hepatic 
complications and complex drug regimens, personalized 
patient care is critical [18, 23, 24]. It is thought that a multi-
disciplinary team (MDT) approach inclusive of a prospective 
assessment of potential drug–drug interactions (DDIs) (prior 
to commencing HCV therapy), improves clinical outcomes 
and cure rates [25, 26].
In the UK, during 2016, twenty two Hepatitis C Opera-
tional Delivery Networks (ODNs) were launched to simplify 
patient access pathways to HCV testing and treatment ser-
vices. The model encompasses a ‘hub and spoke’ approach 
with access to treatment being regulated by the hub that 
supports a specialised multi-disciplinary team to facilitate 
services at both the hub and at the spoke sites. This special-
ist team receives referrals of complicated, comorbid cases 
and ensures prospective evaluations and decision making for 
individualised patient care [27].
Alongside the implementation of the hepatitis C ODN 
within the UK, The National Health Service England 
(NHSE) introduced a hepatitis C treatment run rate card that 
sets clear prescribing guidelines for the hepatitis C regimens 
based on regimen prices. The guidelines stated that 90% 
of patients had to receive first line treatment, and that the 
use of second or third line treatment required review and 
approval from NHSE. As a result of the implementation of 
these guidelines, the MDT team were encouraged to make 
changes to the patients existing co-prescribed medication 
in order to avoid DDIs and comply with the run rate card, 
in preference to prescribing second or third line regimens.
Aim of the study
This study aimed to explore the treatment choices; taking 
into account the prospective identification of DDIs by spe-
cialist pharmacist and to compare clinical outcomes, in HCV 
mono-infected patients, and HCV patients with HIV or CKD 
comorbidities.
Ethics approval
The University Hospitals Birmingham (UHB) research and 
development committee reviewed this study and classified 
this as a service evaluation, hence not requiring full ethical 
submission. Necessary approval was then sought from the 
HR and the Clinical Audit Registration and Management 
System (CARMS-14077).
Method
An observational study was undertaken. Datasets of all HCV 
monoinfected patients and with HIV/CKD comorbidities 
that were referred to a large tertiary Liver Unit in the West 
Midlands, UK, between July 2015 and January 2018 were 
analyzed.
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Patients aged ≥ 18 years with diagnosis of hepatitis C 
alone or co-infected with HIV or comorbid with CKD were 
eligible for this study. Pregnant females, children and HCV 
patient having comorbidities other than HIV or CKD were 
excluded. The relevant patients were identified through the 
database of hospital portal.
Data collection and analysis
A data collection tool was designed and moderated amongst 
the team of researchers including a senior medical consult-
ant, a specialist pharmacist and a statistician. The data 
extraction was carried out by the study researcher and vali-
dated by the specialist pharmacist. Demography, ethnicity, 
mode of acquiring infection (sexual contact, IDU/people 
who inject drugs (PWID), perinatal exposure, iatrogenic 
exposure and other [tattoos, needle piercing, unknown]), 
genotype, baseline HCV viral load, HIV viral load, CD4 
count, liver health status and data of monoinfected patients 
were collected from the tertiary liver unit databases and from 
the Clinical Portal (electronic interface containing patient 
records). Information detailing treatment history, medication 
prescribed was extracted from Clinical Portal/Prescribing, 
Information and Communication System (PICS) and referral 
forms (Appendix 1). The HCV regimen choice, along with 
any advice provided by the specialist pharmacist relating 
to the treatment choice, monitoring requirements and any 
requirements to change the patients existing medications 
were extracted from the correspondence found on clinical 
portal, minutes of the multi-disciplinary team meeting and 
PICS. Any missing information was pursued via request to 
the referring centre and follow up records were reviewed up 
to 12 weeks post end of treatment date.
Non-invasive transient elastography (using Echosens 
touch 502C scanner) was used to generate a fibroscan score 
which was used to determine the non-cirrhotic/cirrhotic sta-
tus of each patient. A fibroscan score of 11.5 kPa or above 
was regarded as cirrhotic liver for the purpose of the study.
Follow up and treatment outcomes were assessed based 
on HCV viral load measured at beginning of treatment, at 
end of treatment (ETR) and 12 weeks post end of treatment 
[12 weeks Sustained Virological Response (SVR)]. A viral 
load of < 12 IU/ml 12 weeks post end of treatment was con-
sidered as undetectable level and was regarded as a cure. The 
final cure rate was reported in terms of modified intention 
to treat % (mITT %; considering the successfully treated 
patients and excluding patients who did not commence the 
treatment, stopped treatment early, those who were lost to 
follow up or were awaiting SVR12). The assessment of 
DDIs was carried out by the specialist pharmacist using the 
hepatitis C drug–drug interaction checker; Liverpool Uni-
versity, the electronic medicine compendium (eMC) for each 
drug and their clinical expertise. A coding tool was used 
to code DDIs. This tool was checked for face and content 
validity by the British Hepatitis Pharmacist Group (BHPG) 
which includes consultant pharmacist and specialist pharma-
cists working within the field of Hepatitis (Appendix 2). The 
codes explain risk rating and action required for potential 
drug–drug interactions.
All the data sets (anonymised) were sought from IT 
department at the tertiary centre and stored on password 
protected computers at all times. Statistical analyses were 
performed using SPSSV.24 (SAS Institute, Cary, NC). Fre-
quency distribution and descriptive statistics were applied 
to demographic and baseline parameters. The Pearson Chi 
square test was applied to assess any difference of demo-
graphic, baseline and end point variables among groups and 
P value of 0.05 or less were taken as statistically significant.
Results
A total of 313 patients met the inclusion criteria, of those 
154 (49.2%) were HCV monoinfected, 124 (39.6%) HCV/
HIV co-infected and 35 (11.2%) were HCV/CKD comorbid. 
The mean (SD) age was 51.9 (11.1) years. Two hundred and 
thirty four (74.8%) were male and 180 (57.5%) were white. 
Genotype 1a was the most prevalent 113 (36.1%) followed 
by genotype 3/3a—110 (35.1%). A total of 102 (32.6%) 
patients were PWIDs. Overall, one hundred and ninety two 
(61.3%) were non-cirrhotic while cirrhosis was diagnosed in 
121 (38.7%) patients (Tables 1, 2).  
In treatment choices, sofosbuvir (Sof)/ledipasvir 
(Led) ± ribavirin (R) was the most (n = 37) prescribed com-
bination of DAAs for non-cirrhotic/treatment naive patients 
ombitasvir (Omb)/paritapravir (Par)/ritonavir (Rit)/dasabu-
vir (Das) ± R was the second most prescribed combination 
(n = 23) and elbasvir (Elb)/grisepravir (Grz) ± R being the 
third most prescribed combination (n = 19) for this group of 
patients. Seventeen of the non-cirrhotic/treatment experi-
enced patients received Omb/Par/Rit/Das ± R. There were 
17 of cirrhotic/treatment naïve patients who were pre-
scribed Sof/daclatasvir (Dac) ± R, while in cirrhotic/treat-
ment experienced patients, Sof/Led ± R was prescribed to 20 
patients. Figure 1 shows the range of treatment combinations 
prescribed.
The treatment choices were markedly influenced by geno-
type of HCV and appropriate selection of treatment regi-
men by MDT sustained individualized care. Resultantly, 
the patients with G1a were prescribed Sof/Led/+, − R 
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(n = 55), Omb/Par/Rit/Das/+, − R (n = 30) and Elb/Grz/+, 
− R (n = 21). Similarly, patients having G3 infection were 
prescribed Sof/Dac/R (n = 42) Glecaprevir (Gle)/Pib (n = 18) 
and Sof/Velpatasvir (Vel)/+ , − R (n = 15).
Clinical outcomes
A total 151 (98.1%) of HCV monoinfected, 110 (88.7%) 
of HCV/HIV and 20 (57.1%) of HCV/CKD patients were 
treated with 1st line HCV treatment in line with NHSE 
recommendations. Significantly more patients who had 
co-morbidity with either HIV or CKD were prescribed 2nd 
line regimens (n = 10, 8.1% and n = 13, 37.1% respectively), 
compared to patients with HCV monoinfection (n = 3, 1.9%) 
(P value < 0.05). Two (1.6%) of HCV/HIV patients were 
treated with 3rd line regimens. Two cases were deferred in 
each of HCV/HIV and HCV/CKD groups as change in con-
comitant medication was required (Table 2).
Table 1  Demographic characteristics of patients; HCV, co-infected HCV/HIV and HCV/CKD (n = 313)
HIV human immunodeficiency virus, CKD chronic kidney disease, SD standard deviation, IDU injecting drug user, PWID patient who inject 
drugs, MSM men who have sex with men
a Viral load is represented as; very low viremic = less than 8000  IU/ml, low viremic = 8001–20,000  IU/ml, moderate viremic = 20,001–
800,000 IU/ml, and high viremic = greater than 800,000 IU/ml
Demographic characteristics Total (n = 313)
n (%)
HCV (n = 154)
n (%)
HCV/HIV (n = 124)
n (%)
HCV/CKD (n = 35)
n (%)
Gender
Female 79 (25.2) 50 (32.5) 16 (12.9) 13 (37.1)
Male 234 (74.8) 104 (67.5) 108 (87.1) 22 (62.9)
Age (years)
Mean (SD) 51.9 (11.1) 50.3 (12.4) 46.10 (10.4) 59.23 (10.6)
Ethnicity/race
Asian or Asian British 47 (15.0) 32 (20.8) 3 (2.4) 12 (34.3)
White 180 (57.5) 56 (36.4) 104 (83.9) 20 (55.6)
Black, African, Caribbean or black British 21 (6.7) 7 (4.5) 11 (8.9) 3 (8.6)
Mixed or multiple ethnic group 2 (0.6) 1 (0.6) 1 (0.8) –
Other ethnic group 5 (1.6) 5 (3.2) –
Prefer not to say 58 (18.5) 53 (34.4) 5 (4.0) –
Mode of infection
Heterosexual/MSM 10 (3.2) – 8 (6.5) 2 (5.7)
IDU/PWID 102 (32.6) 13 (8.4) 80 (64.5) 9 (25.7)
Iatrogenic/non-occupational 31 (9.9) 8 (5.2) 4 (3.2) 19 (54.3)
Not known 170 (54.3) 133 (86.4) 32 (25.8) 5 (14.3)
Genotype
1/1a 113 (36.1) 39 (25.3) 63 (50.8) 11 (31.4)
1b 50 (16.0) 29 (18.8) 13 (10.5) 8 (22.9)
2 5 (1.6) 3 (1.9) 2 (1.6) –
3/3a 110 (35.1) 70 (45.5) 26 (21.0) 14 (40.0)
4/4d 33 (10.5) 12 (7.8) 19 (15.3) 2 (5.7)
5a 2 (0.6) 1 (0.6) 1 (0.8) –
Baseline viral loada
Very low viremic 14 (4.5) 6 (3.9) 8 (6.5) –
Low viremic 37 (11.8) 11 (7.1) 22 (17.7) 4 (11.4)
Moderate viremic 140 (44.7) 83 (53.9) 42 (33.9) 15 (42.9)
High viremic 122 (39.0) 54 (35.1) 52 (41.9) 16 (45.7)
Liver disease status
Non cirrhotic 192 (61.3) 68 (44.2) 102 (82.3) 22 (62.9)
Cirrhotic 121 (38.7) 86 (55.8) 22 (17.7) 13 (37.1)
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Table 2  Patient’s characteristics, treatment choices and outcomes (n = 313)
HCV hepatitis C virus, HIV human immunodeficiency virus, CKD chronic kidney disease, Tx treatment (1st line, 2nd line, 3rd line are in accordance 
with NHSE hepatitis C treatment run rate card at the time of treatment), SVR sustained virological response, FU follow up, modified ITT modified inten-
tion to treat analysis; representing; Tx of HCV patients was approved at MDT but not commenced and ongoing treatments awaiting 12 week SVR
*Pearson Chi square test shows a significant difference (P value 0.05 or less) of the variable among treated groups
Characteristics (N = 313) HCV (n = 154)
n (%)
HCV/HIV (n = 124)
n (%)
HCV/CKD (n = 35)
n (%)
P value
Genotype
1a 39 (25.3) 63 (50.8) 11 (31.4) < 
0.001*
1b 29 (18.8) 13 (10.5) 08 (22.9)
2 03 (1.9) 02 (1.6) –
3/3a 70 (45.5) 26 (21.0) 14 (40.0)
4/4d 12 (7.8) 19 (15.3) 02 (5.7)
5 01 (0.6) 01 (0.8) –
Tx experience and liver status
Non-cirrhotic/naïve 45 (29.2) 73 (58.9) 17 (48.6) < 
0.001*
Non-cirrhotic/pre-treated 23 (14.9) 29 (23.4) 05 (14.3)
Cirrhotic/naïve 39 (25.3) 14 (11.3) 10 (28.6)
Cirrhotic/pre-treated 47 (30.5) 08 (6.5) 03 (8.6)
Tx choices
1st line 151 (98.1) 110 (88.7) 20 (57.1) < 
0.001*
2nd line 03 (1.9) 10 (8.1) 13 (37.1)
3rd line – 02 (1.6) –
Deferred/med change req. – 02 (1.6) 02 (5.7)
Tx outcomes
Not commenced treatment 01 (0.6) 12 (9.7) 02 (5.7)
Stopped early, lost to FU 02 (1.3), 01 (0.6) 02 (1.6), 07 (5.6) 02 (5.7), 00
Completed treatment 150 (97.4) 103 (83.1) 31 (88.6)
SVR 12 achieved 129 (83.8) 84 (67.7) 26 (74.3) < 
0.001*
ETR achieved/awaiting SVR12 14 (9.1) 15 (12.1) 02 (5.7)
SVR 12 not achieved (failed/relapsed) 07 (4.5) 04 (3.2) 03 (8.6)
mITT % cure rate 95.3% 96.1% 90.3%
Fig. 1  Frequency of treatment 
choices considering liver injury 
and treatment experiences. 
Elb elbasvir/grisepravir, Sof/
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vir, R ribavirin, Peg pegylated 
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ledipasvir, Vel velpatasvir
0
5
10
15
20
25
30
35
40
Elb/ Grz/
+,- R
Gle/ Pib Omb/
Par/ R
Omb/
Par/ Rit/
Das/ +,-
R
Omb/
Par/ Rit/
R
Peg/ R Peg/
Sof/ R
Sim/
Peg/ R
Sof/
Dac/ R
Sof/
Led/ +,-
R
Sof/ R Sof/ Vel/
+,- R
)n(stneitapforeb
mu
N
Treatment choices (types)
Treatment choices offered in line with degree of liver injury and 
experience to previous treatment 
Non-cirrhoc/ Naive Non-cirrhoc/ Pre-treated Cirrhoc/ Naive Cirrhoc/ Pre-treated
 International Journal of Clinical Pharmacy
1 3
Of the total 313 patients, 239 (76.4%) achieved 12 week 
SVR and 31 (9.9%) achieved ETR and were awaiting 
12 week post-treatment evaluation at the end of the study. 
Fourteen (4.5%) failed/relapsed, 6 (1.9%) discontinued treat-
ment early, 8 (2.6%) were lost to follow-up and 15 (4.8%) 
did not progress to commence treatment beyond MDT deci-
sion. The overall mITT % cure rate was 95.1% (Fig. 2 and 
Table 2).
When compared HCV/CKD co-morbid (n = 28, 90.3%) 
patients, a greater percentage of patients with HCV who 
were monoinfected or co-infected with HIV, achieved 
mITT % (95.3% of HCV monoinfected and 96.1% of HCV/
HIV respectively). The treatment choices, treatment out-
comes and mITT % analyses are detailed in Table 2. There 
was no significant difference in treatment response in dif-
ferent ethnic groups; baseline viral load and SVR12 were 
similar in all ethnic groups (Table 2).
Overall, the concomitant medications with potential 
DDIs were cardiovascular medicines 83 (26.4%), psycho-
tropic medications 71 (22.7%), acid suppressants 51 (16.2%) 
Fig. 2  Flow diagram showing 
the treatment outcomes of the 
study cohort. MDT multidis-
ciplinary team, SVR sustained 
virologic response
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Awai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Fig. 3  Frequency of con-
comitant medication prescribed 
along with hepatitis C medi-
cines. PPIs proton pump inhibi-
tors, NSAIDs non-steroidal 
anti-inflammatory drugs, CVS 
cardiovascular system drugs
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[Including lansoprazole, omeprazole, ranitidine], statins 26 
(8.3%) [Including atorvastatin, rosuvastatin, simvastatin, 
pravastatin, fluvastatin] and immunosuppressants (3.8%) 
(Fig. 3).
The median (IQR) number of concomitant medicines 
per patient were 2 (1–4) in HCV monoinfected, 3 (2–5) in 
HCV/HIV (excluding the HIV medications) and 8 (4–9) in 
HCV/CKD patients. The potential DDIs with concomitant 
medications were identified in a total 21 (13.6%) of HCV 
monoinfected patients, 56 (45.2%) of HCV/HIV medication 
and 19 (54.3%) of HCV/CKD medication (Table 3). 
The MDT prospectively assessed the risk of potential 
DDIs and advised interventions/action of grade 3 for 11.6%, 
10.4% and 28.5% patients of HCV-monoinfected, HCV/HIV 
and HCV/CKD groups respectively. Similarly, interventions 
of grade 5 were advised for 1.8%, 12.1% and 25.8% patients 
of HCV mono-infected, HCV/HIV and HCV/CKD groups 
respectively. While, interventions of grade 4 were advised 
for 22.7% of HCV/HIV patients. There were more patients 
(76.2%) in HCV mono-infected group that did not require 
any modification in treatment choices compared to HCV/
HIV (24.2%) and HCV/CKD patients (17.1%) (Fig. 4 and 
Appendix 2).
Discussion
This study reports the selection and clinical effectiveness 
of the treatment choices in patients with HCV and con-
comitant comorbidities; specifically looking at the multi-
disciplinary management of DDIs in hepatitis C treated 
patients in the UK. As per our results, treatment choices 
varied greatly due to the comorbidities. Treatment selec-
tion was made according to the individual patient’s cir-
cumstances as observed in the shifting of 1st line to 2nd 
in treatment choices. This was required more frequently 
in the HIV and CKD comorbid patients. In addition, the 
genotype, previous treatment and the presence of liver cir-
rhosis influenced the treatment choice significantly. The 
non-cirrhotic/treatment naive patients required fewer inter-
ventions and modifications when compared to cirrhotic/
previously treated patients, who required greater interven-
tions and treatment modifications.
This study confirms the importance of multi-disciplinary 
team (MDT) in decision making prospectively for HCV/HIV 
and HCV/CKD complicated cases [28]. This is demonstrated 
by results of mITT % cure rate 95.3%, 96.1% and 90.3% 
of HCV monoinfected, HCV/HIV and HCV/CKD patients 
respectively. A number of patients from both the HCV/HIV 
and the HCV/CKD groups however, either stopped the treat-
ment early or were lost to follow-up. In HCV/HIV group, 
2 (1.6%) patients stopped the treatment early and 7 (5.6%) 
were lost to follow-up, while in CKD, 2 (5.7%) patients Ta
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stopped treatment early due to intolerable side effects. There 
were 4 (3.2%) treatment failures in HCV/HIV and 3 (8.6%) 
treatment failure in HCV/CKD comorbid patients. It’s worth 
noting that patients lost to follow up by the hepatology team 
in the HCV/HIV group, may have simply continued follow 
up by the HIV treating team.
At present, in the study setting, the access to DAA treat-
ment for complicated cases such as those with HIV or CKD 
is dependent upon the referral to a specialist centre. The 
referral permits the specialist team to prospectively assess 
the patient’s clinical needs. This process includes an assess-
ment of potential DDIs which contributes to the decisions 
surrounding the selection of the most appropriate HCV regi-
men. This model supports individualized patient’s care, the 
success of which is reflected in the high cure rates achieved. 
The findings of our study is provides addition in evidence to 
the currently available literature [29, 30] about the impact of 
pharmacist intervention and involvement as part of the MDT 
to address the DDIs associated with HCV management. 
While the burden of DDIs and co-morbidities in HCV have 
been previously illustrated [29], patient outcomes in relation 
to MDT interventions had not been explored before. Find-
ings conforms with literature in other clinical areas which 
have demonstrated that inclusion of pharmacist in MDT with 
specific roles such as customization of treatment choices, 
dose modifications to improve adherence and prevention and 
management can help attain desirable treatment outcomes 
[31, 32].
DAA treatment choices conferred a success rate (mITT% 
cure) of 95.3% in HCV mono-infected and 96.1%, 90.3% 
for HIV and CKD comorbid patients respectively. Other 
comorbidities were common in the overall cohort and conse-
quently the use of concomitant medication having potential 
DDIs was observed high with cardiovascular medicines 83 
(26.4%) and psychotropic medications 71 (22.7%).
Study strengths and limitations
This study has explored the role of multi-disciplinary team 
(MDT) in management of HCV and comorbid patients. Data 
was collected from a large tertiary hospital with adequate 
sample size for the planned statistical analyses of compara-
tive outcome measurements. Validated and recognised data 
sources were used for all information on treatment choices 
and clinical outcomes.
This study has limitations. Firstly, the investigators were 
unable to access the data for mono-infected patients from 
the referring centres as only complicated cases are referred 
0.0
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Comparison of groups in terms of intervenon required at MDT level
Fig. 4  Prospective assessment of DDIs and interventions advised by 
multidisciplinary team (MDT). HCV hepatitis C virus, CKD chronic 
kidney disease, HIV human immunodeficiency virus. Risk rating and 
relevant interventions; 1 = no known drug–drug interaction/no action 
needed, 2 = advice on monitoring or counselling given by pharmacist, 
3 = concomitant drug regimen changed, 4 = DDI with HIV/HCV regi-
men requiring a change in the HIV regimen or additional monitoring 
requirements and 5 = HCV drug regimen changed
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to the tertiary centre. Therefore, the PICS data (available at 
tertiary Liver unit) were used for the mono-infected patients. 
Secondly, the HIV or CKD and related treatment or manage-
ment was ultimately under the control of respective depart-
ments, and thus the hepatitis C MDT relied on the respec-
tive departments to act on recommendations accordingly. 
Finally, this study was specific to the population served by 
the tertiary centre and may not reflect the whole population 
within the UK or further afield. In addition to the limitations 
listed, it’s worth noting at this stage that the study observa-
tion period was pre the introduction of Glecaprevir/pibren-
tasvir, thus patients with genotype 3 (G3) HCV and CKD 
were generally not referred to the MDT during the study 
period since the available treatment at that time contained a 
sofosbuvir back bone which is contraindicated in CKD. The 
population of CKD patient included in the study is small 
and predominantly included Genotype 1 (G1) and G3 HCV 
infections.
Future research
This study highlights the role of a multi-disciplinary health-
care professionals’ input into the management of hepatitis C 
patients co-morbid with HIV or CKD. Based on our results, 
it is recommended that a future research work should include 
other co-morbid patients to explore the success of specialist 
hepatitis MDT regarding treatment outcomes in complex 
cases.
Conclusion
This study shows that treatment pathways permitting 
access to specialised MDT care benefits HCV population 
who have HIV or CKD comorbidities. Individual treatment 
adjustments (in accordance with comorbidities, genotype 
and previous treatment experience) and consideration of 
drug–drug interaction by specialist pharmacist is likely to 
provide successful outcomes in HCV patients co-morbid 
with HIV or CKD.
Appropriate selection of DAAs to target HCV infection 
which presents with comorbidities can be enhanced through 
the inclusion and advice of a specialist pharmacist in a MDT 
setting.
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